Geodon: Effective Atypical Antipsychotic for Schizophrenia and Bipolar Disorder
Geodon
| Product dosage: 20mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 20 | $2.70 | $54.00 (0%) | 🛒 Add to cart |
| 30 | $1.90 | $81.00 $57.00 (30%) | 🛒 Add to cart |
| 60 | $1.42 | $162.00 $85.00 (48%) | 🛒 Add to cart |
| 90 | $1.19 | $243.00 $107.00 (56%) | 🛒 Add to cart |
| 120 | $0.95 | $324.00 $114.00 (65%) | 🛒 Add to cart |
| 180 | $0.86 | $486.00 $154.00 (68%) | 🛒 Add to cart |
| 270 | $0.80 | $729.00 $216.00 (70%) | 🛒 Add to cart |
| 360 | $0.76
Best per pill | $972.00 $274.00 (72%) | 🛒 Add to cart |
| Product dosage: 40mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 10 | $4.60 | $46.00 (0%) | 🛒 Add to cart |
| 20 | $3.15 | $92.00 $63.00 (32%) | 🛒 Add to cart |
| 30 | $2.20 | $138.00 $66.00 (52%) | 🛒 Add to cart |
| 60 | $1.58 | $276.00 $95.00 (66%) | 🛒 Add to cart |
| 90 | $1.37 | $414.00 $123.00 (70%) | 🛒 Add to cart |
| 120 | $1.27 | $552.00 $152.00 (72%) | 🛒 Add to cart |
| 180 | $1.21 | $828.00 $218.00 (74%) | 🛒 Add to cart |
| 270 | $1.18 | $1242.00 $319.00 (74%) | 🛒 Add to cart |
| 360 | $1.16
Best per pill | $1656.00 $418.00 (75%) | 🛒 Add to cart |
Geodon (ziprasidone) is an atypical antipsychotic medication approved for the treatment of schizophrenia and acute manic or mixed episodes associated with bipolar disorder. It functions by modulating dopamine and serotonin activity in the brain, offering a favorable side effect profile compared to first-generation antipsychotics. This medication is available in both oral capsule and intramuscular injection formulations, providing flexibility in administration based on clinical needs and patient circumstances. Geodon represents a well-established option in psychiatric pharmacotherapy, supported by extensive clinical evidence and two decades of real-world use.
Features
- Active ingredient: Ziprasidone hydrochloride
- Available formulations: Oral capsules (20 mg, 40 mg, 60 mg, 80 mg) and intramuscular injection (20 mg/mL)
- Mechanism: Dopamine D2 and serotonin 5-HT2A receptor antagonist
- Half-life: Approximately 7 hours (oral)
- Bioavailability: 60% when taken with food
- Metabolism: Primarily hepatic via aldehyde oxidase and CYP3A4
- Excretion: Primarily fecal (66%) with minor renal elimination (20%)
Benefits
- Effective reduction of positive and negative symptoms in schizophrenia
- Rapid stabilization of acute manic symptoms in bipolar disorder
- Lower risk of extrapyramidal symptoms compared to conventional antipsychotics
- Minimal weight gain potential compared to other atypical antipsychotics
- Reduced propensity for metabolic side effects including hyperlipidemia and glucose dysregulation
- Flexible dosing options with both oral and acute intramuscular formulations
Common use
Geodon is primarily indicated for the treatment of schizophrenia in adults, demonstrating efficacy in reducing positive symptoms (hallucinations, delusions) and negative symptoms (social withdrawal, apathy). It is also approved for acute treatment of manic or mixed episodes in bipolar I disorder, either as monotherapy or as an adjunct to lithium or valproate. Some off-label uses include maintenance treatment in bipolar disorder and adjunctive treatment in treatment-resistant depression, though these applications require careful clinical consideration. The intramuscular formulation is particularly valuable in emergency settings for rapid tranquilization of agitated patients.
Dosage and direction
For schizophrenia treatment, initiate at 20 mg twice daily with food. Dosage may be increased to 60 mg or 80 mg twice daily based on clinical response and tolerability. For bipolar mania, begin with 40 mg twice daily, increasing to 60 mg or 80 mg twice daily if needed. The maximum recommended dose is 80 mg twice daily. Intramuscular administration: 10-20 mg every 2 hours up to maximum 40 mg daily. All oral doses must be taken with at least 500 calories of food to ensure optimal absorption. Dosage adjustments are necessary in hepatic impairment but not typically required in renal impairment.
Precautions
Geodon carries a black box warning regarding increased mortality in elderly patients with dementia-related psychosis. ECG monitoring is recommended at baseline and during dose titration due to potential QTc prolongation. Patients should be monitored for neuroleptic malignant syndrome, tardive dyskinesia, and metabolic parameters. Caution is advised in patients with cardiovascular disease, cerebrovascular disease, or conditions predisposing to hypotension. Regular assessment of electrolyte levels (particularly potassium and magnesium) is recommended during treatment. Patients should avoid dehydration and excessive heat exposure during therapy.
Contraindications
Geodon is contraindicated in patients with known hypersensitivity to ziprasidone or any component of the formulation. It must not be used in patients with a history of QT prolongation or recent acute myocardial infarction. Concomitant use with other drugs that prolong QT interval (including Class IA and III antiarrhythmics, certain antipsychotics, antibiotics, and other QT-prolonging agents) is contraindicated. The medication is not recommended in patients with uncompensated heart failure or significant hepatic impairment. Geodon is contraindicated in patients with dementia-related psychosis due to increased mortality risk.
Possible side effect
Common adverse reactions (≥5% incidence) include somnolence (14%), respiratory tract infection (8%), extrapyramidal symptoms (8%), dizziness (8%), and nausea (8%). Other reported effects include headache, constipation, dyspepsia, rash, and orthostatic hypotension. QTc prolongation (mean 10 msec at recommended doses) requires monitoring. Rare but serious side effects include neuroleptic malignant syndrome, tardive dyskinesia, seizures, and allergic reactions. Metabolic effects are generally mild, with weight gain averaging 1-2 kg in clinical trials. Injection site reactions may occur with intramuscular administration.
Drug interaction
Geodon metabolism involves CYP3A4, requiring caution with strong inhibitors (ketoconazole increases AUC by 35-40%) and inducers (carbamazepine decreases AUC by 35%). Concomitant use with other CNS depressants (alcohol, benzodiazepines, opioids) may enhance sedation. Antihypertensive agents may potentiate orthostatic hypotension. Drugs that prolong QT interval (including methadone, moxifloxacin, and certain antidepressants) should be avoided. Lithium and valproate coadministration does not require dosage adjustment. Dopamine agonists may have reduced efficacy when used with Geodon.
Missed dose
If a dose is missed, it should be taken as soon as remembered unless it is nearly time for the next scheduled dose. In that case, skip the missed dose and resume the regular dosing schedule. Do not double the dose to make up for a missed administration. Patients should maintain consistent timing of doses to ensure stable drug levels. If multiple doses are missed, consultation with a healthcare provider is recommended before resuming treatment, as dose titration may be necessary.
Overdose
Symptoms of overdose may include sedation, tremor, hypotension, and QT prolongation. In cases of suspected overdose, immediate medical attention is required. Management includes cardiac monitoring for QT prolongation and arrhythmias, supportive care including maintaining airway and blood pressure, and activated charcoal if presentation is early. There is no specific antidote for ziprasidone overdose. Hemodialysis is not expected to be effective due to high protein binding and extensive metabolism. Extended monitoring is recommended due to the drug’s pharmacokinetic profile.
Storage
Store Geodon capsules at controlled room temperature (20-25°C or 68-77°F) with excursions permitted between 15-30°C (59-86°F). Keep in original container protected from light and moisture. The intramuscular formulation should be stored at room temperature and protected from light. Do not freeze. Keep all medications out of reach of children and pets. Discard any unused medication appropriately according to local regulations, avoiding flushing or disposal in household trash when possible.
Disclaimer
This information is for educational purposes only and does not constitute medical advice. Geodon is a prescription medication that should only be used under the supervision of a qualified healthcare professional. Individual response to medication may vary, and treatment decisions should be based on comprehensive clinical evaluation. Patients should not adjust dosage or discontinue treatment without consulting their prescribing physician. Full prescribing information including boxed warnings should be reviewed before initiation of therapy.
Reviews
Clinical trials demonstrate Geodon’s efficacy with 40-60% of schizophrenia patients showing significant improvement in PANSS scores. In bipolar mania studies, response rates of 50-65% were observed on Young Mania Rating Scale. Real-world evidence supports maintained efficacy with long-term use, though individual responses vary. Many clinicians appreciate its metabolic profile, though some note the twice-daily dosing requirement and food restrictions as potential adherence challenges. Patient reviews frequently mention improved symptom control with fewer metabolic concerns compared to other antipsychotics, though some report initial sedation or gastrointestinal effects.